KR960703901A - 치환된 2(5H)푸라논, 2(5H)티오페논 및 2(5H)피롤론 유도체, 그의 제조 방법 및 엔도텔린 길항제로서의 그의 용도(Substituted 2(5H)Furanone, 2(5H)Thiophenone and 2(5H)Pyrrolone Derivatives, Their Preparation and Their Use as Endothelin antagonists) - Google Patents

치환된 2(5H)푸라논, 2(5H)티오페논 및 2(5H)피롤론 유도체, 그의 제조 방법 및 엔도텔린 길항제로서의 그의 용도(Substituted 2(5H)Furanone, 2(5H)Thiophenone and 2(5H)Pyrrolone Derivatives, Their Preparation and Their Use as Endothelin antagonists)

Info

Publication number
KR960703901A
KR960703901A KR1019960700841A KR19960700841A KR960703901A KR 960703901 A KR960703901 A KR 960703901A KR 1019960700841 A KR1019960700841 A KR 1019960700841A KR 19960700841 A KR19960700841 A KR 19960700841A KR 960703901 A KR960703901 A KR 960703901A
Authority
KR
South Korea
Prior art keywords
hydroxy
furan
methoxyphenyl
dioxol
benzo
Prior art date
Application number
KR1019960700841A
Other languages
English (en)
Korean (ko)
Inventor
켄트 앨런 베리먼
아네트 매리언 도오티
제레미 죤 에드먼드
윌리엄 체스터 패즈
마크 스티븐 플러머
죠셉 토마스 레핀
Original Assignee
로즈 암스트롱
워너-램버트 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 로즈 암스트롱, 워너-램버트 캄파니 filed Critical 로즈 암스트롱
Publication of KR960703901A publication Critical patent/KR960703901A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/41—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by hydrogenolysis or reduction of carboxylic groups or functional derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/72—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction of compounds containing >C = O groups with the same or other compounds containing >C = O groups
    • C07C45/74—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction of compounds containing >C = O groups with the same or other compounds containing >C = O groups combined with dehydration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/02—Saturated compounds having —CHO groups bound to acyclic carbon atoms or to hydrogen
    • C07C47/105—Saturated compounds having —CHO groups bound to acyclic carbon atoms or to hydrogen containing rings
    • C07C47/11—Saturated compounds having —CHO groups bound to acyclic carbon atoms or to hydrogen containing rings monocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/20—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms
    • C07C47/235—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/80—Ketones containing a keto group bound to a six-membered aromatic ring containing halogen
    • C07C49/813—Ketones containing a keto group bound to a six-membered aromatic ring containing halogen polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/60—Two oxygen atoms, e.g. succinic anhydride
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1019960700841A 1993-08-19 1994-08-09 치환된 2(5H)푸라논, 2(5H)티오페논 및 2(5H)피롤론 유도체, 그의 제조 방법 및 엔도텔린 길항제로서의 그의 용도(Substituted 2(5H)Furanone, 2(5H)Thiophenone and 2(5H)Pyrrolone Derivatives, Their Preparation and Their Use as Endothelin antagonists) KR960703901A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US10975193A 1993-08-19 1993-08-19
US08/109,751 1993-08-19
US21757894A 1994-03-24 1994-03-24
US08/217,578 1994-03-24
US27888294A 1994-07-26 1994-07-26
US08/278,882 1994-07-26
PCT/US1994/009091 WO1995005376A1 (fr) 1993-08-19 1994-08-09 Derives de 2(5h)furanone, 2(5h)thiophenone et 2(5h)pyrrolone substitues, leur preparation et leur utilisation en tant qu'antagonistes de l'endotheline

Publications (1)

Publication Number Publication Date
KR960703901A true KR960703901A (ko) 1996-08-31

Family

ID=27380718

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960700841A KR960703901A (ko) 1993-08-19 1994-08-09 치환된 2(5H)푸라논, 2(5H)티오페논 및 2(5H)피롤론 유도체, 그의 제조 방법 및 엔도텔린 길항제로서의 그의 용도(Substituted 2(5H)Furanone, 2(5H)Thiophenone and 2(5H)Pyrrolone Derivatives, Their Preparation and Their Use as Endothelin antagonists)

Country Status (13)

Country Link
US (2) US5691373A (fr)
EP (1) EP0714391A1 (fr)
JP (1) JPH09501920A (fr)
KR (1) KR960703901A (fr)
AU (1) AU693110B2 (fr)
CA (1) CA2165567A1 (fr)
CZ (1) CZ40996A3 (fr)
FI (1) FI960671A (fr)
HU (1) HUT74179A (fr)
NO (1) NO960629L (fr)
NZ (1) NZ271833A (fr)
SK (1) SK20396A3 (fr)
WO (1) WO1995005376A1 (fr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6492413B2 (en) 1993-01-15 2002-12-10 G.D. Searle & Co. 3.4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents
US6541498B2 (en) 1993-05-20 2003-04-01 Texas Biotechnology Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6613804B2 (en) 1993-05-20 2003-09-02 Encysive Pharmaceuticals, Inc. Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US6342610B2 (en) 1993-05-20 2002-01-29 Texas Biotechnology Corp. N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6376523B1 (en) 1994-05-20 2002-04-23 Texas Biotechnology Corporation Benzenesulfonamides and the use thereof to modulate the activity of endothelin
GB9602877D0 (en) * 1996-02-13 1996-04-10 Merck Frosst Canada Inc 3,4-Diaryl-2-hydroxy-2,5- dihydrofurans as prodrugs to cox-2 inhibitors
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
WO1995018799A1 (fr) * 1994-01-10 1995-07-13 Merck Frosst Canada Inc. Heterocycles phenyliques utilises comme inhibiteurs de cox-2
US6162927A (en) 1994-08-19 2000-12-19 Abbott Laboratories Endothelin antagonists
US5767144A (en) * 1994-08-19 1998-06-16 Abbott Laboratories Endothelin antagonists
US7208517B1 (en) 1994-08-19 2007-04-24 Abbott Labortories Endothelin antagonists
US5691374A (en) * 1995-05-18 1997-11-25 Merck Frosst Canada Inc. Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors
WO1997002265A1 (fr) * 1995-07-06 1997-01-23 Warner-Lambert Company ANTAGONISTES DE l'ENDOTHELINE BUTENOLIDIQUE
US5922759A (en) * 1996-06-21 1999-07-13 Warner-Lambert Company Butenolide endothelin antagonists
US6017952A (en) * 1995-08-02 2000-01-25 Smithkline Beecham Corporation Endothelin receptor antagonists
US5998468A (en) * 1995-08-24 1999-12-07 Warner-Lambert Company Furanone endothelin antagonists
US5981576A (en) * 1995-10-13 1999-11-09 Merck Frosst Canada, Inc. (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
US6020343A (en) * 1995-10-13 2000-02-01 Merck Frosst Canada, Inc. (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
US5977117A (en) 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
DE19607096A1 (de) * 1996-02-24 1997-08-28 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
AU2077897A (en) * 1996-04-10 1997-10-29 Warner-Lambert Company Nonpeptide endothelin antagonists with increased water solubility
AU2529297A (en) * 1996-04-10 1997-10-29 Warner-Lambert Company Ketoacid endothelin antagonists
WO1997037986A1 (fr) * 1996-04-10 1997-10-16 Warner-Lambert Company Antagoniste de l'endotheline avec groupes lies a l'ether
US5804585A (en) 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
GB9615867D0 (en) * 1996-07-03 1996-09-11 Merck & Co Inc Process of preparing phenyl heterocycles useful as cox-2 inhibitors
AU3459697A (en) * 1996-07-23 1998-02-10 Shionogi & Co., Ltd. Novel pyrimidine compounds and drug compositions
DE19653037A1 (de) * 1996-12-19 1998-06-25 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
US6030975A (en) * 1997-03-14 2000-02-29 Basf Aktiengesellschaft Carboxylic acid derivatives, their preparation and use in treating cancer
DE19711428A1 (de) * 1997-03-19 1998-09-24 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
EE04156B1 (et) 1997-04-28 2003-10-15 Texas Biotechnology Corporation Sulfoonamiidid endoteliini vahendatud haiguste ravimiseks
US5783705A (en) 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
JP4058507B2 (ja) 1997-07-10 2008-03-12 国立大学法人 東京医科歯科大学 ４，５−ジヒドロ−［１Ｈ］−ベンズ［ｇ］インダゾール−３−カルボン酸誘導体
DE19731571A1 (de) * 1997-07-23 1999-01-28 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
US6080876A (en) * 1997-10-29 2000-06-27 Merck & Co., Inc. Process for making phenyl heterocycles useful as COX-2 inhibitors
WO1999052888A1 (fr) * 1998-04-08 1999-10-21 Washington Odur Ayuko Derives butenolidiques agent anticancereux
DE19818732A1 (de) * 1998-04-27 1999-10-28 Bayer Ag Arylphenylsubstituierte cyclische Ketoenole
JP3850596B2 (ja) * 1999-02-25 2006-11-29 本州化学工業株式会社 新規な部分保護トリスフェノール類とその製造方法
CN1093539C (zh) * 1999-11-02 2002-10-30 中国科学院上海有机化学研究所 一种合成β一卤代丁烯酸内酯的方法
AU2464301A (en) 1999-12-31 2001-07-16 Encysive Pharmaceuticals Inc. Sulfonamides and derivatives thereof that modulate the activity of endothelin
GB0003671D0 (en) * 2000-02-17 2000-04-05 Univ Cardiff Diphenyl-substituted lower alkanes
GB0007401D0 (en) 2000-03-27 2000-05-17 Cancer Res Campaign Tech Substituted chalcones as therapeeutic compounds
US6610747B2 (en) 2000-08-31 2003-08-26 Pfizer Inc. Phenoxybenzylamine derivatives as SSRIs
WO2002018333A1 (fr) * 2000-08-31 2002-03-07 Pfizer Limited Derives de la phenoxybenzylamine inhibiteurs selectifs du recaptage de la serotonine
US7329782B2 (en) * 2001-06-12 2008-02-12 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
GB0123777D0 (en) * 2001-10-03 2001-11-21 Cancer Res Ventures Ltd Substituted chalcones as therapeutic agents
GB0123780D0 (en) 2001-10-03 2001-11-21 Cancer Res Ventures Ltd Substituted chalcones as therapeutic agents
US7235580B2 (en) * 2002-10-18 2007-06-26 Merck & Co., Inc. Mitotic kinesin inhibitors
CN1328271C (zh) * 2005-06-21 2007-07-25 浙江大学 一种合成β－碘代丁烯酸内酯的方法
WO2006136423A2 (fr) * 2005-06-24 2006-12-28 Dsm Ip Assets B.V. Nouvelle utilisation de composes organiques
US20090203773A1 (en) * 2005-06-24 2009-08-13 D Orazio Daniel Compounds for the Treatment of Non-Autoimmune Type 2 Diabetes Mellitus and/or Syndrome X
US7537774B2 (en) * 2005-12-23 2009-05-26 Orion Therapeautics, Llc Therapeutic formulation
RU2435585C2 (ru) * 2006-04-13 2011-12-10 Актелион Фармасьютиклз Лтд Антагонисты рецептора эндотелина, предназначенные для ранней стадии идиопатического фиброза легких
US9221751B2 (en) 2009-11-26 2015-12-29 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
US10722575B2 (en) 2009-11-26 2020-07-28 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
ES2681794T3 (es) * 2009-11-26 2018-09-17 Genfit Uso de derivados de 1,3-difenilprop-2-en-1-ona para tratar trastornos hepáticos
FR3026607A1 (fr) * 2014-10-03 2016-04-08 Centre Nat Rech Scient Composes permettant la conservation de cellules, tissus et organes, compositions et utilisations
CN110963932B (zh) * 2019-11-25 2021-06-04 中南大学 查尔酮衍生物及其制备方法和在抗弓形虫中的应用
CN111393421B (zh) * 2020-04-07 2021-08-31 自然资源部第三海洋研究所 丁烯酸内酯类衍生物及其制备方法与应用
CN111925281B (zh) * 2020-09-04 2022-04-15 江苏恩华药业股份有限公司 一种盐酸戊乙奎醚杂质2-环戊基-2-苯基乙醛的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ190995A (en) * 1978-09-05 1982-03-09 American Cyanamid Co Substituted omega propionyl or butyryl l-prolines and pharmaceutical compositions
JPS5916884A (ja) * 1982-07-19 1984-01-28 Fujisawa Pharmaceut Co Ltd 新規フラン化合物
IT1169783B (it) * 1983-08-25 1987-06-03 Roussel Maestretti Spa Derivati dell' acido 4-fenil 4-osso-buten 2-oico, loro procedimento di preparazione e loro applicazione come prodotti medicinali
US4968817A (en) * 1984-07-27 1990-11-06 National Distillers And Chemical Corporation Manufacture of gamma-crotonolactone by carbonylation of glycidol
DE3920271A1 (de) * 1989-06-21 1991-01-03 Bayer Ag N-aryl-stickstoffheterocyclen
CA2032559C (fr) * 1989-12-28 2001-11-06 Kiyofumi Ishikawa Pentapeptides cycliques antagonistes de l'endotheline
WO1991016055A1 (fr) * 1990-04-17 1991-10-31 Allergan, Inc. 2(5h)-furanones substituees dans les positions 5 et/ou 4, utilisees comme agents anti-inflammatoires
US5183906A (en) * 1991-04-30 1993-02-02 Allergan, Inc. 2- and 5-alkyl and phenyl substituted 4-(1-hydroxy, 1-acyloxy or 1-carbamoyloxy)-5-hydroxy-2 (5h)-furanones as anti-inflammatory agents
JPH05178706A (ja) * 1991-12-27 1993-07-20 Sumitomo Chem Co Ltd 有害節足動物忌避剤
AU4547896A (en) * 1995-02-03 1996-08-21 Banyu Pharmaceutical Co., Ltd. 4-oxo-2-butenoic acid derivatives

Also Published As

Publication number Publication date
SK20396A3 (en) 1997-03-05
HUT74179A (en) 1996-11-28
JPH09501920A (ja) 1997-02-25
FI960671A (fi) 1996-04-19
NO960629D0 (no) 1996-02-16
US5691373A (en) 1997-11-25
EP0714391A1 (fr) 1996-06-05
NZ271833A (en) 1997-08-22
CA2165567A1 (fr) 1995-02-23
HU9600365D0 (en) 1996-04-29
AU693110B2 (en) 1998-06-25
WO1995005376A1 (fr) 1995-02-23
CZ40996A3 (en) 1996-09-11
US6017916A (en) 2000-01-25
AU7561794A (en) 1995-03-14
FI960671A0 (fi) 1996-02-14
NO960629L (no) 1996-02-16

Similar Documents

Publication Publication Date Title
KR960703901A (ko) 치환된 2(5H)푸라논, 2(5H)티오페논 및 2(5H)피롤론 유도체, 그의 제조 방법 및 엔도텔린 길항제로서의 그의 용도(Substituted 2(5H)Furanone, 2(5H)Thiophenone and 2(5H)Pyrrolone Derivatives, Their Preparation and Their Use as Endothelin antagonists)
RU2205827C2 (ru) Производное ацилпиперазинилпиримидина, способы его получения, фармацевтическая композиция
RU2359967C2 (ru) Производные тиофена и фармацевтическая композиция (варианты)
RU2312101C2 (ru) Цис-имидазолины в качестве ингибиторов mdm2
RU2393156C2 (ru) Замещенные гидантоины для лечения рака
JP2008509982A5 (fr)
TWI388323B (zh) 基於吡唑之肝ｘ受體（ｌｘｒ）調節劑
RU2401260C2 (ru) Пиримидиновые производные
RU2005124359A (ru) Пирролилтиазолы и их применение в качестве обратных агонистов рецептора св 1
JP2009520686A5 (fr)
RU2004127925A (ru) N3-алкилированные бензимидазольные производные в качестве ингибиторов мек
RU2000104007A (ru) Производные ацилпиперазинилпиримидинов, их получение и применение в качестве лекарственных средств
RU2004125582A (ru) Хиназолин(ди)оны для борьбы с беспозвоночными вредителями
ZA200508623B (en) Use of derivatives of 2,4-dihydro-[1,2,4]triazole-3-thione as inhibitors of the enzyme myeloperoxidase (MPO)
KR20060002818A (ko) Ｃ-글리코시드 유도체 또는 이의 염
JP2006524686A5 (fr)
RU2012125763A (ru) Спироиндолинонпирролидины
RU2006117635A (ru) Производные индолинона и их применение для лечения патологических состояний, таких как злокачественное новообразование
RU2350609C2 (ru) Производные бензофурана и бензотиофена, применяемые при лечении гиперпролиферативных заболеваний
AU622881B2 (en) New 2,5-diaryl tetrahydrofurans and analogs thereof as paf antagonists
KR20060066677A (ko) 칸나비노이드 수용체 조절제
RU2001121196A (ru) Новые производные простого пропаргилового эфира
CA2405408A1 (fr) Composes de pyrazole
RU96113141A (ru) Производные 5,6-дигидропирона в качестве ингибитора протеазы и антивирусные средства
US4006137A (en) 2-Ethenyl imidazolium derivatives

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid